Sigyn Therapeutics Reports Third Quarter 2023 Financial Results

On November 14, 2023 Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB: SIGY), a development-stage medical technology company, reported its financial results for the third quarter ended September 30, 2023 (Press release, Sigyn Therapeutics, NOV 14, 2023, View Source [SID1234637639]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the quarter, the Company continued its plan to initiate first-in-human studies of Sigyn TherapyTM and further advanced its endeavors to develop pipeline technologies to enhance the performance of cancer therapies. The initial treatment indication of Sigyn TherapyTM is being directed toward end-stage renal disease (ESRD) patients with endotoxemia, a condition that is highly prevalent and associated with increased mortality in the ESRD population. The Company has identified three clinical site locations and is working with principal investigators to finalize the study protocol. Once finalized, the Company intends to submit an Investigational Device Exemption (IDE) to The U.S. Food and Drug Administration (FDA) requesting permission to enroll up to 15 ESRD subjects with the primary objective to demonstrate the safety of Sigyn TherapyTM.

Summary of Third Quarter 2023 Financial Results

For the quarter ended September 30, 2023, the Company had a loss from operations of approximately $642,814, compared to an operating loss of approximately $533,647 for the comparable period of 2022. The Company’s net loss for the 2023 third quarter was approximately $905,726 or approximately $0.02 per share, compared to a net loss of approximately $726,509, or approximately $0.02 per share, for the comparable period in 2022.

For complete financial results, please see Sigyn Therapeutics’ filings at www.sec.gov, and on the Company’s website at www.SigynTherapeutics.com under "Financial Info" in the Investors section.